Please login to the form below

benralizumab

This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).

FDA rejects GSK’s Nucala for COPD

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).
AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Tezepelumab is a thymic stromal lymphopoietin (TSLP) targeting antibody that would slot into AZ’s key respiratory portfolio alongside Fasenra (benralizumab), the company’s interleukin-5 inhibitor antibody which was approved
New cancer drugs can’t quite plug the revenue hole at AZ

Fasenra (benralizumab) although overall respiratory sales were flat in the first half at $2.41bn.
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

NICE has published draft guidance recommending Fasenra (benralizumab), AstraZeneca’s treatment for people who have severe eosinophilic asthma.
PMCPA takes AZ to task over asthma drug press release

body. The source of GSK’s anger was a PR put out by AZ after interleukin-5 inhibitor Fasenra (benralizumab) was recommended for approval by the EMA’s Committee for Medicinal ... In the complaint, GSK maintained that the statement that benralizumab

More from news
Approximately 8 fully matching, plus 33 partially matching documents found.

Deal Watch March 2017

In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)
Pharma deals in July 2015

In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Add my company

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....